Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® to Parkinson’s Disease

Clinical-Stage Biotech Company Reports Patent Filing Based on Preclinical Data Using “Regenerative Immunotherapy” Approach

PHOENIX, May 24, 2021 / PRNewswire / – Creative Medical Technology Holdings, traded under the symbol CELZ, today announced positive preclinical data supporting the extension of the applicability of ImmCelz® to Parkinson’s disease. Using the well-established MPTP mouse model of the disease, administration of ImmCelz® has been shown to inhibit the onset of Parkinson-like behavior and result in protection of dopaminergic cells. It is important to note that the increase in the brain protective protein interleukin-10 was observed in the treated animals.

Logo Creative Medical Technology Holdings, Inc. (PRNewsfoto / Creative Medical Technology Hol)

The Company is pleased to note that the concept of “regenerative immunotherapy” appears applicable to many indications, particularly in the field of neurological diseases.

The ImmCelz® product uses the patient’s own blood cells that have been “reprogrammed” by culture with established universal donor stem cells followed by reinfusion into the patient. To date, preclinical models of hepatic failure1, Diabetes2stroke3, rheumatoid arthritis4, and now Parkinson’s disease has been shown to respond to ImmCelz® therapy.

“According to the Parkinson Foundation, there are 1 million patients with this disease in the United States, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy and amyotrophic lateral sclerosis (ALS)5. ” Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “We are committed to advancing our primary indication for ImmCelz®, which is stroke, for which we are currently responding to comments provided by the FDA before we can initiate human trials. Once human trials are cleared for stroke, we plan to initiate trials in other indications for which we have seen preclinical efficacy, thus creating a large portfolio of products for this first-class approach we call immunology. regenerative. “

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in regenerative medicine / stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the symbol CELZ. For more information about the company, please visit

Forward-looking statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements deal with future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at

Timothy warbington, CEO

1 Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in a Preclinical Model (
2 Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes | BioSpace
3 Creative Medical Technology Announces Successful Application of ImmCelz Immunotherapy for Stroke | American Pharmaceutical Review – The Review of American Pharmaceutical Business and Technology
4 Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace
5 Statistics | Parkinson Foundation



View original content to download multimedia:

SOURCE Creative Medical Technology Holdings, Inc.

Source link

Leave a reply